2019-03-05| Technology

Novo Nordisk Pharma Ltd. Partners with Health2Sync in Japan, Bringing Digital Diabetes Management to Healthcare Providers and Patients

by GeneOnline
Share To

Tokyo, Japan and Taipei, Taiwan, March 5th, 2019 – Health2Sync and Novo Nordisk Pharma Ltd. are partnering in Japan to support digital diabetes management and facilitate communication between diabetics and healthcare providers. Last December, the two companies agreed to support the localization and promotion of the “SyncHealth” App (known as Health2Sync outside of Japan) and web platform for patient management.

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given Novo Nordisk experience and capabilities that also enable it to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Novo Nordisk recognises the need for solutions beyond medicines. Therefore, Novo Nordisk and Health2Sync are partnering to promote digital health strategy by providing support tools, services and programs that can contribute to improving outcomes of patients.

Health2Sync was founded in 2013, which provides a comprehensive health management platform for people with diabetes. It combines mobile, cloud, and data analytics, enabling patients to obtain personalized care, and allowing care providers and family members to care for patients remotely.

People living with diabetes require constant vigilance in making the right lifestyle choices and remembering to take their medications. Health2Sync bridges the lengthy gap between doctor visits by enabling frequent digital touch points between patients and healthcare providers. Through its behavioral AI engine, the App can provide hints and nudges concerning meals, exercise, and blood glucose management, delivered in a compelling and friendly way that encourages users to stay adherent to their treatment plans.

As part of the partnership, Novo Nordisk Pharma Ltd. will support the distribution and adoption of the SyncHealth app and healthcare provider platform in Japan. In the future, Novo Nordisk Pharma Ltd. aims to wirelessly connect its insulin delivery devices, enabling auto data recording of self-injected insulin. The SyncHealth App and the SyncHealth Platform are products developed for people living with diabetes, and H2 is solely responsible and liable for the products’ usage. Also, when providing such products or services, H2 directly acquires user data (including personal information) after obtaining user’s consent, and H2 is fully responsible and liable for preserving and processing such data.


© All rights reserved. Collaborate with us:
Related Post
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
APAC Leading the Industry in Adoptive Cell Therapy – Trials, Economic Growth, and Pioneering Companies
Taiwan’s Biotech and Pharma Delegation: Innovations Take Center Stage at BIO 2024
Breaking Ground in Alzheimer’s with 10 Cutting-Edge Treatments Paving the Way in 2024
Merck Buys EyeBio for $3B and Shares Global Policy Perspectives During BIO in San Diego
Johnson & Johnson’s Bispecific Antibodies for Atopic Dermatitis and Talks of Biotech Partnerships at BIO 2024
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
SINBON and MAKALOT partner to drive cross-industry textile wearable adoption
Scroll to Top